Back to top
more

Dova Pharmaceuticals, Inc. (DOVA)

(Delayed Data from NSDQ)

$9.62 USD

9.62
129,426

+0.18 (1.91%)

Updated May 3, 2019 04:00 PM ET

After-Market: $9.64 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[DOVA]

Reports for Purchase

Showing records 1 - 20 ( 32 total )

Industry: Medical - Drugs

Record: 1

11/12/2019

Daily Note

Pages: 6

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 2

11/12/2019

Company Report

Pages: 4

Dropping Coverage Due to Acquisition

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 3

10/14/2019

Daily Note

Pages: 25

Biotechnology - Down But Not Out: Looking Ahead to 3Q19 Biotech Reporting

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 4

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for DOVA

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 5

10/04/2019

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 6

10/03/2019

Company Report

Pages: 6

Downgrade to Neutral, Raising Price Target to $29 Following Acquisition Bid

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 7

09/30/2019

Daily Note

Pages: 4

No One Like You: Sobi to Acquire DOVA for Up to $29/Share

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 8

09/30/2019

Company Report

Pages: 6

Happy Monday; SOBI to Take out Dova; Downgrade to Neutral, $27.50 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 9

09/23/2019

Industry Report

Pages: 11

Biotechnology - Hematology KOL Dinner Offers In-Depth Look Across ITP, PNH Landscapes

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 10

09/19/2019

Company Report

Pages: 14

Time to Start Paying Attention to Next Phase 3 Data Readout

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 11

08/16/2019

Industry Report

Pages: 10

Biotechnology - Overcoming Challenges in CNS Drug Development

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 12

08/14/2019

Daily Note

Pages: 4

Conference Takeaways: Encouraged By ITP Launch, CIT On Track

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 13

08/14/2019

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 14

08/06/2019

Company Report

Pages: 6

2Q19 Results; Blocking and Tackling Continues; Eyes on ITP Launch; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 15

08/06/2019

Company Report

Pages: 11

2Q19 EPS Clearing the Deck for ITP Launch

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 16

07/17/2019

Daily Note

Pages: 4

On the Road Again... DOVA Management Travel Arrives at Opportune Time

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 17

07/17/2019

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 18

07/16/2019

Daily Note

Pages: 21

Biotechnology - Ahead of 2Q19 Biotech Reporting - Thoughts on Commercial Names

Provider: WEDBUSH SECURITIES INC.

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 19

07/12/2019

Industry Report

Pages: 10

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 20

06/28/2019

Company Report

Pages: 10

Doptelet Starting to Get Interesting - ITP Approval, CIT Credit

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party